The efficacy of denosumab and zoledronic acid as treatment for prostate cancer

Share :
Published: 8 Jul 2010
Views: 8127
Dr Karim Fizazi - Institut Gustave Roussy, France

Dr Karim Fizazi discusses his phase III trial which compared the efficacy of denosumab with zoledronic acid in patients with matastatic castration-resistant prostate cancer. The trial demonstrated that denosumab is superior to zoledronic acid in delaying or preventing skeletal-related events. Dr Fizazi goes on to outline his aims for further research into denosumab and explains the side-effects that the treatment can have on the patients.

This interview is supported by an unrestricted educational grant from AMGEN.